Phase IIb AMP Studies: In Vitro Susceptibility of HIV-1 Isolates to Broadly Neutralizing Antibody VRC01 Predicts HIV Prevention Efficacy in MSM, Transgender Persons, and Cisgender Women

January 27-28 and February 3-4, 2021
This pooled analysis of the phase IIb AMP studies observed that in vitro susceptibility of circulating HIV-1 isolates to the broadly neutralizing antibody, VRC01, predicts prevention efficacy in MSM, transgender persons, and cisgender women.
Format: Microsoft PowerPoint (.ppt)
File Size: 292 KB
Released: February 3, 2021


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

CCO expert commentary on key studies from HIVR4P // Virtual 2021 on PrEP, implementation strategies, multipurpose prevention technologies, and more

Kenneth Mayer, MD Released: February 25, 2021

Commentary from Dr. Kenneth Mayer on data from HIVR4P 2021 on immunoprophylaxis and multipurpose prevention as PrEP, from Clinical Care Options (CCO)

Kenneth Mayer, MD Released: February 18, 2021

Expert selections of the most important data from HIVR4P 2021 Virtual, including PrEP clinical trials, implementation strategies and more, from CCO

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD Kenneth Mayer, MD Released: February 17, 2021

Commentary from Dr. Beatriz Grinsztejn on new data from HIVR4P 2021 on long-acting PrEP islatravir and cabotegravir, from Clinical Care Options (CCO)

Beatriz Grinsztejn, MD, PhD Released: February 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.